Resmed (RSMDF) Equity Income (2018 - 2026)

Resmed (RSMDF) has reported Equity Income for 9 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Equity Income rose 75.97% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $7.0 million (up 90.86% YoY), and the FY2026 full-year result was $7.0 million, up 90.86% from the prior year.
• Equity Income improved to $2.2 million in Q2 2026 per RSMDF's latest filing, from $1.7 million in the prior quarter.
• Across five years, Equity Income topped out at $2.2 million in Q2 2026 and bottomed at -$3.9 million in Q3 2023.
• Historically, Equity Income has averaged -$205555.6 across 5 years, with a median of $589500.0 in 2023.
• The sharpest annual moves came in 2022 and 2026: Equity Income tumbled 95.34% in 2022, then jumped 412.84% in 2026.
• Over 5 years, Equity Income stood at -$2.8 million in 2022, then jumped by 126.15% to $739000.0 in 2023, then jumped by 45.74% to $1.1 million in 2024, then soared by 40.67% to $1.5 million in 2025, then soared by 47.39% to $2.2 million in 2026.
• According to Business Quant data, Equity Income over the past three periods registered $2.2 million, $1.7 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.